FEL D1 Major Allergen I Polypeptide Chain 1 Antigenic Blocking Peptide C-Epitope Blocking Peptide

A number of house pet bourn allergens have been studied for allergic reactions in general population. Domestic cat (Felis domestica) is an important source of indoor allergen Fel D1 that affects a large opulation. Fel Dl is also established to cause catinduce asthma in sensitive patients. The levels of Fel D1 nd Can Fl were high in homes of former pet-owners compared to the homes without pets. Children with ild allergy to animal dander may have profound increase in bronchial sensitivity (increased sputum osinophil peroxidase (EPO) and myeloperoxidase (MPO) activity as a result of constant exposure of nimal allergens (Fel D1 and Can Fl) at public places. Allergic reactions to Fel D1 are effectively reduced y conventional immunotherapy in many patients, but this type of irnmunotherapy has severe reactions, ncluding anaphylaxis and requires several years of injections for successful desensitization. Several trategies have been employed to address these issues including use of cat allergen peptides, chimeric onstructs of Fel D1 and Fc portion of human lgEs (1). The synthetic cat allergen peptides lack the tertiary tructure of native Fel D1 and posses reduced capacity to bind Fel D1-specific lgE. These peptides when iven to patients sensitive to cat allergens showed improvement in pulmonary function and tolerance to ats (1). The exposure of chimeric human -cat fusion protein composed of truncated human lgGFcgammal nd the Fel Dl . The chimeric protein induces dose dependent inhibition of Fel D1-driven lgE mediated istamine release form cat allergic donors (2). The allergen is a 38 kDa dimer composed of two 19 kDa subunits. ach 19 kDa subunit comprises two disulfide linked polypeptide chains, a light alpha-chain and a heavy beta-chain containing an N-linked ligosaccharide. The alpha light chain and the heavy beta chain are linked in an anti-parallel configuration. The Fel Dl glycosylation at Asn 3 is of heterogeneous triantennary structure caused by terminal sialic acid and fructose residues attached to beta-galactose residues. FabGennix has developed anti-Fel D1-selective antibodies against 3 epitopes covering the majority of the protein. The affinity purified ono- pecific polyclonal antibodies to FEL D1 strongly labels a 15-18 kDa protein in cat saliva samples examined. MBS employs cyclic eptide methodology for generating antibodies, which results in higher titer and specificity. Western blot positive control in readyto-use DS-sample buffer (PC-FELDI ) and antigenic blocking peptide (P-FELD1 .3) are available. Antibodies can be conjugated with fluorescent robes or other secondary enzymes upon request at extra charge.

Small volumes of FEL D1 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS543670 is a blocking peptide targeting FEL D1. Also known as FEL D1 Major Allergen I Polypeptide Chain 1 Antigenic Blocking Peptide C-epitope.